Gastric function measurements in drug development

Department of Medicine B, University of Münster, Albert-Schweitzer-Strasse 33, D-48129 Münster, Germany.
British Journal of Clinical Pharmacology (Impact Factor: 3.69). 09/2003; 56(2):156-64. DOI: 10.1046/j.1365-2125.2003.01935.x
Source: PubMed

ABSTRACT The function of the stomach includes initiation of digestion by exocrine secretions such as acid and pepsin, which are under the control of the endocrine secretion of hormones that also coordinate intestinal motility. The stomach also stores and mechanically disrupts ingested food. Various techniques have been developed to assess gastric physiology, the most important of which is assessment of acid secretion, as well as gastric motility and gastric emptying. The influence of drugs on gastric function and the effect of gastric secretion and mechanical actions on the bioavailability of novel compounds are of critical importance in drug development and hence to clinical pharmacologists. The control of acid secretion is essential in the treatment of peptic ulcer disease as well as gastrooesophageal reflux disease (GORD); pH-metry can be used to determine the necessary dose of an acid suppressant to heal mucosal damage. Disturbed gastric myoelectric activity leading to gastroparesis can cause delayed gastric emptying, often found in patients with diabetes mellitus. Electrogastrography (EGG) may be used to evaluate the influence of prokinetics and other drugs on this condition and aid in determining effective therapy.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A wireless motility capsule is a new method for ambulatory assessment of transit times and motility throughout the gastrointestinal tract. The objective of this study was to evaluate the ability of a wireless motility capsule to detect drug effects on gastric emptying time (GET) and gastric contractility. 15 healthy adults were administered in random order saline, erythromycin IV 150 mg, or morphine IV 0.05 mg/kg BW. Subjects ate a standard meal after each infusion, and subsequently ingested the motility capsule. Data were recorded for 8 hours, and the results were analyzed using the manufacturer's software. GET was significantly faster after erythromycin than either saline or morphine. Morphine tended to delay emptying of the capsule compared to saline. There was a trend toward a greater frequency of gastric contractions with erythromycin and a reduced frequency of gastric contractions with morphine that did not reach statistical significance. A wireless motility capsule successfully detected acceleration of gastric emptying induced by erythromycin, and retardation of gastric motility caused by morphine. These results indicate that a wireless motility capsule is a promising technique to assess pharmacologic effects on gastric transit and contractility and aid in development of drugs for gastric motor disorders.
    BMC Gastroenterology 01/2014; 14(1):2. DOI:10.1186/1471-230X-14-2 · 2.11 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Proton pump inhibitors are potent gastric acid-suppressing agents and belong to the most widely sold drugs in the world. However, even though these antisecretory agents are regarded as safe, they can show several interactions with co-administered drugs. Due to the suppression of gastric acid secretion, the can significantly alter the intragastric pH-conditions and are thus likely to affect the bioavailability of co-administered drugs requiring an acidic gastric environment for dissolution and subsequent absorption. Among these drugs, itraconazole, a poorly soluble triazole-type antifungal compound can be found. Based on observations reported in the literature, gastric pH-alterations due to the co-administration of PPIs or acidic beverages can significantly decrease (PPI) or increase (e.g. Coca-Cola®) the bioavailability of this compound. In the present work we tried to estimate the fraction of itraconazole that can be absorbed (fabs) from Sporanox® capsules or an itraconazole-HBenBCD complex formulation after oral admistration with and without co-administration of a PPI or an acidic (carbonated) beverage. For this purpose, the sensitivity of the two formulations towards the impact of various gastric variations (pH, volume and emptying rate) as they can result from such administration conditions was studied using solubility and dissolution experiments and a physiologically based absorption model. Simulating co-administration of the two formulations with a PPI resulted in a significant (~10 fold) decrease in itraconazole fabs, indicating the pH to be essential for in-vivo dissolution and subsequent absorption. Itraconazole's fabs after co-administered acidic beverage (Coca-Cola®) that was far lower than the fabs obtained for itraconazole alone, did not support the observations reported in the literature. These results clearly indicate that in contrast to PPIs, which seem to affect itraconazole bioavailability mainly via intragastric pH changes, co-administered Coca-Cola® is likely to alter a range of gastrointestinal parameters relevant to in-vivo dissolution rather than solely affecting the intragastric pH.
    Molecular Pharmaceutics 08/2013; 10(11). DOI:10.1021/mp4003249 · 4.79 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The magnetic capsule endoscope has been modified to be fixed inside the stomach and to monitor the gastric motility. This pilot trial was designed to investigate the feasibility of the magnetic capsule endoscope for monitoring gastric motility. The magnetic capsule endoscope was swallowed by the healthy volunteer and maneuvered by the external magnet on his abdomen surface inside the stomach. The magnetic capsule endoscope transmitted image of gastric peristalsis. This simple trial suggested that the real-time ambulatory monitoring of gastric motility should be feasible by using the magnetic capsule endoscope.
    Journal of neurogastroenterology and motility 04/2014; 20(2):261-4. DOI:10.5056/jnm.2014.20.2.261 · 2.70 Impact Factor


Available from